[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 10970
1. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood; 2005 Dec 1;106(12):3733-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
  • Nucleophosmin (NPM1) exon-12 gene mutations are the hallmark of a large acute myelogenous leukemia (AML) subgroup with normal karyotype, but their prognostic value in this AML subset has not yet been determined.
  • We screened 401 AML patients with normal karyotype treated within the German AML Cooperative Group Protocol 99 (AMLCG99) study for NPM1 mutations.
  • The favorable impact of NPM1 mutations on OS and EFS clearly emerged in the large group (264 [66.8%] of 395 cases) of normal-karyotype AML without FLT3-LM.
  • This positive effect was lost in the presence of a concomitant FLT3-LM, since survival of the NPM1+/FLT3-LM+ double positive was similar to NPM1-/FLT3-LM+ cases.
  • In conclusion, this study demonstrates that NPM1+/FLT3-LM- mutations are an independent predictor for a favorable outcome in AML with normal karyotype.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. Disease-Free Survival. Female. Humans. Male. Middle Aged. Mutation. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076867.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


2. Middeldorf I, Galm O, Osieka R, Jost E, Herman JG, Wilop S: Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML). Am J Hematol; 2010 Jul;85(7):477-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML).
  • In older patients suffering from acute myelogenous leukemia (AML), aggressive chemotherapy is accompanied with high treatment-related morbidity and mortality.
  • Consequently, a variable response of AML cells to anti-CD33-targeted therapy may be caused by modulation of SOCS3 expression.
  • Twenty-four patients with refractory or relapsed CD33-positive AML received GO as a single agent before or after conventional chemotherapy.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. DNA Methylation. Leukemia, Myeloid, Acute / drug therapy. Salvage Therapy / methods. Suppressor of Cytokine Signaling Proteins / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20575043.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / SOCS3 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; 0 / gemtuzumab
  •  go-up   go-down


3. Raaijmakers MH, de Grouw EP, van der Reijden BA, de Witte TJ, Jansen JH, Raymakers RA: ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3452-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia.
  • PURPOSE: Acute myelogenous leukemia (AML) is a disease originating from normal hematopoietic CD34+ CD38- progenitor cells.
  • Modulation of the multidrug ATP-binding cassette transporter ABCB1 has not resulted in improved outcome in AML, raising the question whether leukemic CD34+ CD38- cells are targeted by this strategy.
  • Surprisingly, ABCB1-mediated drug extrusion was invariably reduced in CD34+ CD38- cells in AML (n = 15; EI, 1.21 +/- 0.05; P < 0.001), which resulted in increased intracellular mitoxantrone retention in these cells (mitoxantrone fluorescence intensity, 4.54 +/- 0.46 versus 3.08 +/- 0.23; P = 0.004).
  • These data argue that ABCB1 modulation is not an effective strategy to circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal progenitors in AML.
  • [MeSH-major] Hematopoietic Stem Cells / drug effects. Leukemia, Myeloid, Acute / drug therapy. P-Glycoprotein / drug effects

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3231-2 [16740740.001]
  • (PMID = 16740770.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antigens, CD34; 0 / Antigens, Differentiation; 0 / CBFbeta-MYH11 fusion protein; 0 / Cyclosporins; 0 / Oncogene Proteins, Fusion; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 121584-18-7 / valspodar; BZ114NVM5P / Mitoxantrone; CJ0O37KU29 / Verapamil; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


Advertisement
4. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC: Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res; 2008 Mar 1;14(5):1446-54
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
  • PURPOSE: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro.
  • We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML).
  • Nine patients had relapsed AML (ages, 18-59 years, n = 4 and > or = 60 years, n = 5).
  • There were 22 patients of > or = 60 years with previously untreated AML (eight with prior myelodysplasia/myeloproliferative disorder or cytotoxic therapy).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Leukemia, Myeloid, Acute / metabolism

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316568.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA066996
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Boronic Acids; 0 / Pyrazines; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib; ZRP63D75JW / Idarubicin
  •  go-up   go-down


5. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer; 2009 Jan 1;115(1):101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
  • BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children.
  • METHODS: A total of 641 patients with de novo ALL who were treated with the hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen or its variants were analyzed.
  • RESULTS: Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients).
  • At the time of ALL diagnosis, the median age was 53 years; cytogenetics were normal in 11 patients, pseudo-diploidy with del(2) in 1 patient, t(9;22) in 1 patient, and unavailable in 3 patients.
  • Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients.
  • Secondary AML/MDS developed at a median of 32 months after ALL diagnosis.
  • Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS.
  • Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation.
  • The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months).
  • CONCLUSIONS: Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


6. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, Rijnders BJ: Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis; 2008 Dec 15;47(12):1507-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
  • BACKGROUND: Invasive aspergillosis (IA) is a leading cause of mortality in patients with acute leukemia.
  • METHODS: In 269 patients treated for acute myelogenous leukemia-myelodysplastic syndrome (AML-MDS) during 2002-2007, evidence of IA was collected using high-resolution computed tomography and galactomannan measurement in bronchoalveolar lavage fluid specimens.
  • CONCLUSIONS: Early diagnosis and treatment of IA with oral voriconazole result in acceptable mortality rates.
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Aspergillosis / economics. Drug Therapy / economics. Health Care Costs. Leukemia, Myeloid, Acute / complications


7. Christiansen L, Allen RA, Dunn ST, Wolff DJ: A case of infantile acute myelogenous leukemia with MLL-MLL10 fusion caused by insertion of 11q into 10p. Cancer Genet Cytogenet; 2005 Jun;159(2):181-3
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of infantile acute myelogenous leukemia with MLL-MLL10 fusion caused by insertion of 11q into 10p.
  • [MeSH-major] Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 11. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Artificial Gene Fusion. Child, Preschool. Chromosome Aberrations. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Myeloid-Lymphoid Leukemia Protein. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899395.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / MLLT10 protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


8. Kesari S, Akar S, Saad A, Drappatz J, Koralnik IJ, DeAngelo DJ: Progressive multifocal leukoencephalopathy in a patient with relapsed acute myelogenous leukemia. J Clin Oncol; 2008 Aug 1;26(22):3804-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive multifocal leukoencephalopathy in a patient with relapsed acute myelogenous leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukoencephalopathy, Progressive Multifocal / etiology


9. Lee SE, Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Kim DW, Lee JW, Park CW, Kim CC: Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. Int J Hematol; 2010 Sep;92(2):342-50
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
  • To define the role of RIC in AML with old age (>or=55 years) and/or co-morbidities (HCT-CI scores >or=2), we analyzed patients who received allogeneic stem cell transplantation (SCT) with Flu/Bu/TBI 400 cGy/+/-antithymocyte globulin (ATG) conditioning regimen.
  • Calcineurin inhibitor and a short course of standard dose methotrexate were used to prevent graft-versus-host disease (GVHD).
  • The incidence of acute (grades II-IV) and chronic GVHD by NIH consensus criteria was 34.4 and 62.5%.
  • This study suggests that the Flu/Bu/TBI 400 cGy or Flu/Bu/TBI 400 cGy/ATG-based conditioning regimens maybe a feasible therapeutic approach for AML with old age and/or co-morbidities.
  • [MeSH-major] Busulfan / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Vidarabine / analogs & derivatives. Whole-Body Irradiation / methods
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents. Antineoplastic Agents, Alkylating. Comorbidity. Female. Humans. Leukemia, Myeloid, Acute. Male. Middle Aged. Survival Analysis. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694843.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


10. Gassas A, Ishaqi MK, Afzal S, Finkelstein-Shechter T, Dupuis A, Doyle J: A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center. Bone Marrow Transplant; 2008 Jun;41(11):941-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center.
  • We reviewed 70 consecutive children with AML who received hematopoietic stem cell transplantation (HSCT) in our institution between 1994 and 2005.
  • Expectedly, there was a significant increase in acute GVHD incidence in CR2 patients (40 vs 25% for grades I-II and 30 vs 10% for grades III-IV; P=0.02) and a significant increase in transplant-related mortality (38 vs 11%; P=0.01).
  • Although the difference between 3-year EFS for CR1 and CR2 was not statistically significant, there was a significantly superior 3-year overall survival for CR1 patients (74 vs 51%; P=0.05).
  • Children with relapsed AML who achieve and maintain remission until HSCT, have a reasonable survival, but the outcome of children receiving HSCT in CR1 remains superior.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Hospitals, Pediatric. Humans. Infant. Male. Remission Induction. Retrospective Studies. Transplantation Conditioning. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264141.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Schiller GJ, O'Brien SM, Vey N, Pigneux A, DeAngelo DJ, Karp JE, Hudak D, Kell J, Stuart RK, Giles FJ: Comorbidity description using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in elderly de novo poor-risk AML patients (pts) treated with laromustine. J Clin Oncol; 2009 May 20;27(15_suppl):7050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity description using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in elderly de novo poor-risk AML patients (pts) treated with laromustine.
  • : 7050 Background: Treatment of older pts with AML is often complicated by comorbidities and pts with comorbidities are often underrepresented in clinical trials.
  • The HCT-CI, which was developed in pts receiving allogeneic SCT, has been applied to pts receiving induction therapy for AML in an effort to assist in therapeutic and investigational decisions (Kantarjian 2006; Etienne 2007; Giles 2007).
  • HCT-CI scores have been shown to be predictive of early death and survival in pts ≥ 60 years receiving induction therapy for AML, with early death rates of 3%, 11%, and 29% for pts with HCT-CI scores of 0, 1-2, and ≥ 3, respectively (Giles 2007).
  • METHODS: 140 pts age ≥ 60 with poor risk de novo AML from two phase II studies were scored for comorbidity by HCT-CI.
  • CONCLUSIONS: The majority (81%) of these older poor risk AML pts treated with laromustine had a HCT-CI score ≥ 3, confirming the poor risk nature of this patient group.
  • The induction death rate for pts treated with laromustine and with HCT-CI score ≥ 3 was lower than that reported for a group of pts with HCT-CI score ≥ 3 treated with standard induction chemotherapy (14% vs 29%; Giles 2007).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961414.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Chamberlain MC, Raizer J: Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia. J Clin Oncol; 2009 May 20;27(15_suppl):e13030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML).
  • The diagnosis of tMDS was determined by bone marrow biopsy in seven patients.
  • Three patients were diagnosed with AML as well (in two determined by bone marrow and one at autopsy).
  • Interval from last chemotherapy exposure to diagnosis of tMDS/AML ranged from 3 months to 31 months (median 24 months).
  • Five patients have died, two as a consequence of recurrent brain tumor, one as a complication of transplantation, and due due to AML.
  • CONCLUSIONS: Although rare, induction of tMDS/AML following extended use of alkylator-based chemotherapy may become more relevant with the evolving practice to treat gliomas for protracted periods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962878.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Chaubey R, Sazawal S, Mahapatra M, Saxena R: Low frequency of RAS and absence of FLT3-ITD gene mutations in patients with Myelodysplastic Syndromes in India: AIIMS experience. J Clin Oncol; 2009 May 20;27(15_suppl):e22231

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22231 Background: Chromosomal abnormalities and molecular detection has potential importance for diagnosis and prognosis of MDS, although the mechanisms underlying the development of MDS and their progressive evolution to AML are still largely unknown.
  • Since, no studies have been reported from India on the prevalence of N-RAS, K- RAS point mutation in codon 12 and FLT3-ITD mutations in patients with MDS, we undertook this study.
  • PCR-RFLP and nested PCR-RFLP were used for the detection of point mutation in codon 12 of N-RAS and K-RAS.
  • One out of 53 patients (2%) was found positive for N-RAS and four patients were positive for K-RAS (8%) mutation.
  • The presence of N-RAS codon 12 mutation was associated with the poor survival.
  • FLT3-ITD mutation was not observed in any of our cases, which is in contrast to 3% reported from the West.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964108.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sierra J, Harms R, Mo M, Vogel CL: Evaluation of reported bone pain in patients (pts) receiving chemotherapy in pegfilgrastim clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):9621

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some authors have suggested that pegfilgrastim-induced bone pain is unpredictable and refractory to analgesics (Kirshner 2007), though that impression may not be uniformly accepted.
  • The incidence of bone pain was determined by treatment (pegfilgrastim, filgrastim, or placebo), chemotherapy (taxane-containing or not), cycle, severity, age, and body surface area (BSA).
  • In studies comparing pegfilgrastim (n=74) and filgrastim (n==7) in pts with AML and NHL, 52% were female, and the mean (SD) age was 50 (15.1) years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963898.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Sekeres M, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Berger D: Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS). J Clin Oncol; 2009 May 20;27(15_suppl):7009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five pts experienced serious AEs, and there were 2 cases of disease progression to AML: one pt in the QWSC cohort who received romiplostim for 4 weeks and one in the Q2WSC cohort who received romiplostim for 20 weeks.
  • For pts who completed 8 weeks treatment, 15/23 (65%) achieved a plt response, defined by IWG 2006 criteria, and 14/23 (61%) did not require a plt transfusion during this period.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961381.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, d'Amore F: Tumor-infiltrating CD163-positive macrophages, clinicopathological parameters, and prognosis in classical Hodgkin lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8528 Background: Classical Hodgkin lymphoma (cHL) is characterized by a minority of neoplastic cells surrounded by a heterogeneous background of non-neoplastic cells.
  • CD163 expression was assessed immunohistochemically and the degree of intratumoral LAM infiltration was scored semi-quantitatively.
  • All pts were homogeneously treated with either chemo-radiotherapy (localised disease) or ABVD chemotherapy (advanced disease).
  • The histological subtypes were: nodular sclerosis (NS)-type I, 167 cases (59 %); NS-type II, 71 (25%); mixed cellularity (MC), 44 (15 %); lymphocyte-rich, lymphocyte-depleted and cHL-NOS, each one case.
  • Of 253 pts with assessable International Prognostic Score (IPS), 204 had a low-risk (≤ 2) and 49 a high risk (>2) profile.
  • Furthermore, a high expression of CD163 strongly correlated to stage IV disease (p=0.035), presence of B-symptoms (p=0.008), lymphocytopenia (p=0.003), hypersedimentation (p=0.009).
  • CONCLUSIONS: In cHL, a high number of intratumoral CD163+ monocytes/macrophages correlates with adverse outcome and with clinical parameters reflecting underlying aggressive disease biology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960903.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Armstrong GT, Pan Z, Ness K, Srivastava D, Robison LL: Temporal trends in cause-specific late mortality among five-year survivors of childhood cancer. J Clin Oncol; 2009 May 20;27(15_suppl):10004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 5-yr survivors, the impact of changes in therapy on cause-specific late mortality has not been thoroughly assessed.
  • Cause-specific mortality was categorized as death from recurrence/progression of primary disease, external causes, and non-recurrence/non-external causes (Non-Recur/Ext) (i.e., deaths from health conditions including sequelae of cancer therapy).
  • No significant improvement in late mortality attributable to Non-Recur/Ext causes was seen.
  • Additionally, all-cause mortality was significantly lower in more recent eras for 5-year survivors of ALL, AML, Hodgkin, NHL, and CNS tumors, but not neuroblastoma and Ewing's Sarcoma where an increase in cumulative incidence of late mortality was seen in more recent eras.
  • CONCLUSIONS: All-cause late mortality has improved with more recent eras, attributable to reduced rates of mortality from progression of primary disease (i.e., durable remission).
  • Importantly, however, efforts to reduce the toxicity of more recent therapies have not produced detectable reduction in mortality attributable to other health conditions including sequelae of cancer therapy (non-Recur/Ext causes of death), which would include death from second malignancy, cardiac and pulmonary conditions.
  • Worsening late mortality for 5-year survivors of neuroblastoma and Ewing's sarcoma may be due to improved use of salvage therapies that delay, but do not ultimately prevent death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962548.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Queudeville M, Eckhoff SM, Debatin K, Meyer LH: Correlatoin of apoptosis signaling in primary pediatric BCP-ALL xenograft cells with the kinetics of engraftment in vivo in a NOD/SCID model and patient outcome. J Clin Oncol; 2009 May 20;27(15_suppl):10043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10043 Background: We previously identified the importance of intact apoptosis signaling for treatment response in pediatric ALL and AML by analyzing two key apoptogenic events, caspase-3 activation and cytochrome c release.
  • Using a NOD/SCID mouse model for pediatric BCP-ALL we found that short time from transplant to overt leukemia in the recipient mice (short time to leukemia, TTLshort) determines poor patient outcome.
  • METHODS: In this study we investigated the importance of deficient apoptosis signaling for leukemia engraftment in this model.
  • CONCLUSIONS: Our finding in the NOD/SCID/huALL model matches our results in pediatric ALL and AML to conclude that the functional integrity of a downstream apoptotic checkpoint is an important feature regulating leukemia biology.
  • Thus, deficient apoptosis signaling appears to determine rapid engraftment of leukemia cells in the NOD/SCID model in vivo and consequently poor patient outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962469.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Plunkett W, Thomas DA, O'Brien SM, Federl S, Giles FJ, Nicol SJ, Gill J, Zhao L, Ravandi F, Kantarjian H: Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia.
  • The purpose of this phase I trial was to define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of pemetrexed given with vitamin supplementation to patients with relapsed or refractory leukemia.
  • METHODS: Patients ≥15 years of age were enrolled with relapsed or refractory leukemia, Eastern Cooperative Oncology Group performance status ≤2, adequate renal and hepatic function, and life expectancy of ≥6 weeks.
  • RESULTS: Twenty-two patients entered the trial; median age was 50 years (range: 18-75); 15 patients had acute myeloid leukemia and 7 patients had acute lymphocytic leukemia (ALL).
  • Two patients were ineligible and did not receive study drug.
  • At the 1,200 and 1,500 mg/m<sup>2</sup> dose levels, 1 patient per level developed grade (G) 3-4 liver enzyme and bilirubin elevations attributed to sepsis.
  • At the 3,600 mg/m<sup>2</sup> dose level, 1 patient had a G3 liver enzyme elevation and 2 added patients also had G3 liver toxicity.
  • In addition, 2 patients in the 3,600 mg/m<sup>2</sup> cohort developed G2 liver abnormalities.
  • Based on liver toxicities, the DLT dose level was established at 3,600 mg/m<sup>2</sup>.
  • Two patients died during the study due to disease progression and 1 patient discontinued due to a subdural hematoma of unknown cause.
  • PK and PD data were not available for this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Van Der Jagt R, Robinson KS, Belch A, Yetisir E, Wells G, Larratt L, Shustik C, Gluck S, Stewart K, Sheridan D, Canadian Leukemia Studies Group: Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. Leuk Lymphoma; 2006 Apr;47(4):697-706
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
  • PURPOSE: The Canadian Leukemia Studies Group (CLSG) sought to test the safety and efficacy of response-adapted, non-cross resistant chemotherapy in de novo acute myeloid leukemia (AML).
  • Median overall survival (OS) in responding patients < or =60 was not reached: of the 79 responders < or =60, 35 died.
  • The median disease free survival (DFS) in these responding patients was 22.7 (14.9, na) months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690529.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


21. Tallman MS, Mathews V, DiPersio JF: Role of hematopoietic stem cell transplantation in acute myelogenous leukemia and myelodysplastic syndrome. Cancer Treat Res; 2009;144:415-39
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of hematopoietic stem cell transplantation in acute myelogenous leukemia and myelodysplastic syndrome.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Antigens, CD34 / biosynthesis. Bone Marrow Cells / cytology. Disease-Free Survival. Humans. Prognosis. Recurrence. Remission Induction. Risk. Stem Cell Transplantation. Translocation, Genetic. Transplantation, Autologous. Treatment Outcome


22. Hotta K, Kiura K, Takigawa N, Matsuo K, Tabata M, Fujiwara Y, Tanimoto M: Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia. J Clin Oncol; 2008 Dec 10;26(35):5826-7; author reply 5827
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Cell Proliferation / drug effects. Humans. Treatment Outcome


23. Yasukawa K, Kato N, Aikawa K, Kodama K, Hamasaka A, Hata H: Neutrophilic eccrine hidradenitis with sclerodermoid change heralding the relapse of acute myelogenous leukemia: is this a paraneoplastic phenomenon? Dermatology; 2007;215(3):261-4
Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic eccrine hidradenitis with sclerodermoid change heralding the relapse of acute myelogenous leukemia: is this a paraneoplastic phenomenon?
  • [MeSH-major] Hidradenitis / etiology. Leukemia, Myeloid / complications. Paraneoplastic Syndromes / etiology
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / therapeutic use. Humans. Male. Middle Aged. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823528.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Langer F, Steinmetz O, Marx G, Amirkhosravi A, Eifrig B, Bokemeyer C, Brümmendorf T: Aprotinin-associated hemolytic thrombotic microangiopathy in a patient with acute myelogenous leukemia (AML) and systemic coagulopathy. Am J Hematol; 2007 Dec;82(12):1122-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aprotinin-associated hemolytic thrombotic microangiopathy in a patient with acute myelogenous leukemia (AML) and systemic coagulopathy.
  • [MeSH-major] Blood Coagulation Disorders / complications. Hemostatics / adverse effects. Leukemia, Myeloid, Acute / complications. Thrombosis / chemically induced


25. Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA. Best Pract Res Clin Haematol; 2008 Mar;21(1):1-98
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561374.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Congresses; Overall
  • [Publication-country] England
  •  go-up   go-down


26. Verneris MR, Grupp SA: Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time? J Clin Oncol; 2010 Feb 20;28(6):909-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time?
  • [MeSH-major] Cell- and Tissue-Based Therapy. Killer Cells, Natural / transplantation. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085932.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] United States
  •  go-up   go-down


27. Metz KA, Johnson T, Hershey GK, Lierl MB, Seidu L, Burns K, Assa'ad A: Successful administration of cytarabine in a 16-month-old girl with acute myelogenous leukemia and cytarabine syndrome. Ann Allergy Asthma Immunol; 2009 Feb;102(2):173-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful administration of cytarabine in a 16-month-old girl with acute myelogenous leukemia and cytarabine syndrome.
  • [MeSH-major] Cytarabine / adverse effects. Cytarabine / therapeutic use. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • Hazardous Substances Data Bank. RANITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230475.001).
  • [ISSN] 1081-1206
  • [Journal-full-title] Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • [ISO-abbreviation] Ann. Allergy Asthma Immunol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine Antagonists; 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine; 884KT10YB7 / Ranitidine; 8GTS82S83M / Diphenhydramine; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


28. Lu H, Lu SF, Shen WY, Hong M, Zhang JF, Wang LX, Yang H, Li JY: Successful combination therapy with infusion of allogenetic bone marrow mesenchymal stem cells and CAG regimen in hypoplastic relapsed acute myelogenous leukemia. Leuk Res; 2008 Nov;32(11):1776-9
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful combination therapy with infusion of allogenetic bone marrow mesenchymal stem cells and CAG regimen in hypoplastic relapsed acute myelogenous leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells. Leukemia, Myeloid, Acute / therapy. Mesenchymal Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501425.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 74KXF8I502 / Aclarubicin; CAG protocol
  •  go-up   go-down


29. Nishioka C, Ikezoe T, Yang J, Yokoyama A: Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cells. Leukemia; 2009 Dec;23(12):2304-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cells.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Protein Kinase Inhibitors / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Cell Line, Tumor. Drug Delivery Systems / methods. Humans. Interleukin-6 / biosynthesis. Janus Kinase 2 / metabolism. STAT5 Transcription Factor / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675589.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Protein Kinase Inhibitors; 0 / STAT5 Transcription Factor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


30. Wang Y, Chow E, Piliotis E, Tsao M: Initial presentation as sclerotic bone metastases in a patient with acute myelogenous leukemia. J Palliat Med; 2007 Feb;10(1):256-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial presentation as sclerotic bone metastases in a patient with acute myelogenous leukemia.
  • [MeSH-major] Bone Neoplasms / secondary. Leukemia, Myeloid, Acute / pathology. Sclerosis / diagnosis


31. Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A: Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res; 2010 Sep;34(9):1224-31
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.
  • Leukemia cell lines were treated with eltrombopag or thrombopoietin and their proliferative response was determined.
  • Eltrombopag did not increase proliferation of cell lines that did not express high levels of megakaryocyte markers.
  • Instead, treatment with eltrombopag alone inhibited proliferation of many cell lines (IC(50) range=0.56-21 microg/mL).
  • The addition of other cytokines, such as G-CSF, Epo or Tpo, did not affect the decrease in proliferation.
  • These findings suggest that eltrombopag does not enhance, but rather inhibits, proliferation of leukemia cell lines in vitro.
  • [MeSH-major] Benzoates / pharmacology. Hydrazines / pharmacology. Leukemia / pathology. Leukemia, Myeloid, Acute / pathology. Lymphoma / pathology. Pyrazoles / pharmacology
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Cell Proliferation. DNA Primers. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20202683.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoates; 0 / DNA Primers; 0 / Hydrazines; 0 / Pyrazoles; 0 / eltrombopag
  •  go-up   go-down


32. D'Orazio JA, Burns LA, Farhoudi N, McBride MT, Kesler MV: Acute myelogenous leukemia presenting as acute infectious meningitis in a 7-year-old boy. Clin Pediatr (Phila); 2009 May;48(4):444-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia presenting as acute infectious meningitis in a 7-year-old boy.
  • [MeSH-major] Escherichia coli Infections / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Meningitis, Bacterial / diagnosis
  • [MeSH-minor] Aminoglycosides / administration & dosage. Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Blood Cell Count. Bone Marrow / pathology. Ceftriaxone / therapeutic use. Child. Chromosomes, Human, Pair 10. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Flow Cytometry. Humans. Injections, Spinal. Male. Patient Transfer. Spinal Puncture. Trisomy / genetics. Trisomy / pathology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224868.001).
  • [ISSN] 0009-9228
  • [Journal-full-title] Clinical pediatrics
  • [ISO-abbreviation] Clin Pediatr (Phila)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 75J73V1629 / Ceftriaxone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


33. Baylin SB, Mufti GJ: Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction. Nat Clin Pract Oncol; 2005 Dec;2 Suppl 1:S1-3
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. DNA Modification Methylases / antagonists & inhibitors. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy


34. Ryningen A, Ersvaer E, Øyan AM, Kalland KH, Vintermyr OK, Gjertsen BT, Bruserud Ø: Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leuk Res; 2006 Dec;30(12):1531-40
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90.
  • Spontaneous in vitro apoptosis reflects a true biological heterogeneity between patients which has to be considered when in vitro models are used to study regulation of apoptosis in native human AML cells.
  • Even though the balance between pro- and anti-apoptotic signaling seems to have a prognostic impact in AML, the possible clinical relevance of spontaneous apoptosis remains to be clarified.
  • High apoptosis/low viability was associated with low levels of heat shock proteins 70 and 90 as well as low Bcl-2:Bax ratio for patients heterogeneous with regard to morphology, membrane molecule expression, genetic abnormalities and response to therapy.
  • [MeSH-major] Apoptosis. HSC70 Heat-Shock Proteins / metabolism. HSP90 Heat-Shock Proteins / metabolism. Leukemia, Myeloid, Acute / metabolism. Oxidative Stress. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-2-Associated X Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Survival / drug effects. Cells, Cultured. Coculture Techniques. Cytarabine / pharmacology. Female. Flow Cytometry. Gene Expression Profiling. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600371.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / HSC70 Heat-Shock Proteins; 0 / HSP90 Heat-Shock Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; 04079A1RDZ / Cytarabine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


35. Kato J, Mori T, Sugita K, Murata M, Ono Y, Yamane A, Shimizu T, Okamoto S: Central line-associated bacteremia caused by drug-resistant Staphylococcus caprae after chemotherapy for acute myelogenous leukemia. Int J Hematol; 2010 Jun;91(5):912-3
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central line-associated bacteremia caused by drug-resistant Staphylococcus caprae after chemotherapy for acute myelogenous leukemia.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bacteremia / etiology. Cytarabine / administration & dosage. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Staphylococcus / isolation & purification

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20390386.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


36. Bolaños-Meade J, Hartley E, Jones RJ: Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide. Biol Blood Marrow Transplant; 2006 Mar;12(3):366-7
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide.
  • [MeSH-major] Bone Marrow Transplantation. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Leukemia, Myeloid, Acute / mortality. Myeloablative Agonists / administration & dosage


37. Santos FP, Qiao W, Cortes JE, Jones D, Ravandi F, Verma D, Kantarjian H, Borthakur G: Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML).
  • : 7015 Background: Mutations of the FLT3 gene (in special internal tandem duplication -ITD) are common in normal karyotype AML (NK-AML) and are associated with shorter relapse free and overall survival (OS).
  • METHODS: The records of patients (pts) with newly diagnosed AML (from 2003 to 2007) were reviewed.
  • A Cox model was fit for OS, and non-significant variables were eliminated in a step-down fashion with a p- value cut-off of p = .10.
  • No difference was found in median OS between FLT3-mutated and FLT3- wild type pts in the good risk group (not reached (NR) vs NR, P = 0.57) nor in the poor risk group (55 vs 24 weeks, P = 0.44).
  • In intermediate risk, OS was worse in FLT3-ITD positive pts (33 vs 89 weeks, P < 0.0001) but not in FLT3-TKD positive pts (77 vs 70 weeks, P = 0.89).
  • CONCLUSIONS: In our cohort of pts, FLT3 mutations did not have a prognostic impact in AML with good and poor risk karyotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961388.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Takahashi T, Harada S, Oki M, Yoshimoto M, Tsujisaki M, Maemori M, Sakai H: Acute myelogenous leukemia with monosomy 7 in a Hiroshima survivor 60 years after the atomic bomb. Cancer Genet Cytogenet; 2006 Oct 15;170(2):182-3
Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia with monosomy 7 in a Hiroshima survivor 60 years after the atomic bomb.
  • [MeSH-major] Chromosomes, Human, Pair 7. Leukemia, Myeloid / genetics. Leukemia, Radiation-Induced / genetics. Monosomy. Nuclear Warfare
  • [MeSH-minor] Acute Disease. Aged, 80 and over. Humans. Japan. Male. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011994.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


39. Niebuhr B, Iwanski GB, Schwieger M, Roscher S, Stocking C, Cammenga J: Investigation of C/EBPalpha function in human (versus murine) myelopoiesis provides novel insight into the impact of CEBPA mutations in acute myelogenous leukemia (AML). Leukemia; 2009 May;23(5):978-83
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of C/EBPalpha function in human (versus murine) myelopoiesis provides novel insight into the impact of CEBPA mutations in acute myelogenous leukemia (AML).
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / physiology. Leukemia, Myeloid, Acute / genetics. Mutation / genetics. Myelopoiesis / physiology
  • [MeSH-minor] Animals. Cell Differentiation. Colony-Forming Units Assay. Dimerization. Humans. Mice. Myeloid Cells / metabolism. RNA, Small Interfering / pharmacology. Stem Cells / metabolism

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020539.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / CEBPA protein, mouse; 0 / RNA, Small Interfering
  •  go-up   go-down


40. Nakaseko C, Sakaida E, Ohwada C, Ozawa S, Takeuchi M, Shimizu N, Cho R, Yokota A, Saito Y, Nishimura M: Acute fulminant myocarditis after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning for acute myelogenous leukemia. Ann Hematol; 2007 Jan;86(1):67-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute fulminant myocarditis after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning for acute myelogenous leukemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy. Myocarditis / etiology. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Electrocardiography. Graft vs Host Disease / etiology. Humans. Male. Middle Aged. Transplantation, Homologous / adverse effects


41. Athanassiadou F, Kourti M, Tragiannidis A, Papageorgiou T, Haritanti A, Kaloutsi V, Velegraki A: Pulmonary embolism due to invasive aspergillosis in a child with acute myelogenous leukemia. Pediatr Blood Cancer; 2005 Dec;45(7):1001-2
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary embolism due to invasive aspergillosis in a child with acute myelogenous leukemia.
  • [MeSH-major] Aspergillosis / radiography. Leukemia, Myeloid, Acute. Pulmonary Embolism / radiography. Tomography, X-Ray Computed


42. Lee JH, Ha JS: Complex translocation (8;8;21) with additional trisomy 4 in acute myelogenous leukemia. Korean J Hematol; 2010 Jun;45(2):89

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex translocation (8;8;21) with additional trisomy 4 in acute myelogenous leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120185.001).
  • [ISSN] 2092-9129
  • [Journal-full-title] The Korean journal of hematology
  • [ISO-abbreviation] Korean J Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2983018
  •  go-up   go-down


43. Rowe JM: Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)? Leukemia; 2005 Aug;19(8):1324-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Age Factors. Aged. Disease-Free Survival. Humans. Middle Aged. Prospective Studies. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944718.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Addresses
  • [Publication-country] England
  •  go-up   go-down


44. Haimi M, Elhasid R, Moustafa N, Gershoni-Baruch R: Aberration of 3q and monosomy 7 in a child with acute myelogenous leukemia. Cancer Genet Cytogenet; 2007 Apr 1;174(1):78-81
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberration of 3q and monosomy 7 in a child with acute myelogenous leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. Chromosomes, Human, Pair 7 / genetics. Leukemia, Myeloid, Acute / genetics. Monosomy / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350473.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins
  •  go-up   go-down


45. Klepin HD, Balducci L: Acute myelogenous leukemia in older adults. Oncologist; 2009 Mar;14(3):222-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia in older adults.
  • The incidence of acute myelogenous leukemia (AML) increases with age.
  • Older AML patients, generally defined by age > or = 60 years, have worse treatment outcomes than younger patients.
  • While selected older patients can benefit from standard therapies, as a group they experience greater treatment-related toxicity, lower remission rates, shorter disease-free survival times, and shorter overall survival times.
  • Older patients are more likely to present with unfavorable cytogenetic abnormalities, multidrug resistance phenotypes, and secondary AML.
  • Investigations of hypomethylating agents and signal transduction inhibitors hold promise for the treatment of AML patients.
  • [MeSH-major] Geriatrics / methods. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282349.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 72
  •  go-up   go-down


46. Laille E, Ward R, Nasser A, Stoltz M, Cogle C, Gore S, Skikne BS, Garcia-Manero G: The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7087

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML).
  • : 7087 Background: 5-azacitidine (AZA), through its effects on DNA metabolism, gene expression, and cell differentiation, has proven beneficial in treatment of MDS and AML and AZA therapy significantly increases survival in higher-risk MDS and AML compared to conventional care.
  • Few studies have evaluated the pharmacokinetics (PK) of AZA and the renal elimination of AZA has not been previously published to our knowledge.
  • METHODS: Adult patients with MDS or AML and ECOG status 0-2 were treated with 7 consecutive daily SC doses of 75 mg/m<sup>2</sup> AZA during their first treatment cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961481.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Sahu GR, Mishra R, Nagpal JK, Das BR: Alteration of p73 in acute myelogenous leukemia. Am J Hematol; 2005 May;79(1):1-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of p73 in acute myelogenous leukemia.
  • In the present study, we scanned for mutations in the exons 4, 5, 6, and 7 of p73, as well as methylation of the CpG island in the untranslated region of exon 1, in 100 de novo AML patients.
  • The expression level of p73 mRNA was also examined in 40 AML samples using reverse transcriptase-polymerase chain reaction.
  • Only six AML patients showed p73 mRNA expression, as analyzed by RT-PCR analysis.
  • Thus, it is presumed that mutation of p73 might lead to production of defective p73 protein and p73 mRNA, and this might have a role in the process of leukemogenesis of AML.
  • This report is the first demonstrating the presence of mutations in p73 gene in acute myelogenous leukemia.
  • [MeSH-major] DNA-Binding Proteins / genetics. Genes, Tumor Suppressor. Leukemia, Myeloid, Acute / genetics. Mutation. Nuclear Proteins / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • [RetractionIn] Sahu GR, Mishra R, Nagpal JK, Das BR. Am J Hematol. 2008 Aug;83(8):691 [18615454.001]
  • (PMID = 15849769.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


48. Veuillen C, Gravis G, Marcy M, Walz J, Bladou F, Salem N, Brunelle S, Olive D: Alterations of natural killer cells in metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, our group have reported that patients with acute myeloid leukaemia have defective interactions receptor -ligand in NK cells due to a decreasing expression of Natural Cytotoxicity Receptors and it could be used as a evasion mechanism by leukaemia cells.
  • In ADPC and AIPC NK cells, the expression of NKRi and other NKRa did not differ from healthy donors.
  • In LPC NK cells, the expression of NKRi and NKRa did not differ from healthy donors.
  • Is it hormonal therapy or extension of the disease that is responsible of NK cells alterations?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963371.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Rison RA: Ascending sensory motor polyradiculoneuropathy with cranial nerve involvement following administration of intrathecal methotrexate and intravenous cytarabine in a patient with acute myelogenous leukemia: a case report*. Cases J; 2008;1(1):255

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ascending sensory motor polyradiculoneuropathy with cranial nerve involvement following administration of intrathecal methotrexate and intravenous cytarabine in a patient with acute myelogenous leukemia: a case report*.
  • BACKGROUND: Acute inflammatory polyradiculoneuropathy secondary to chemotherapy for leukemia has been described in the pediatric literature.
  • However, the reports are rare and have been mainly from intrathecal methotrexate in pediatric acute lymphoblastic leukemia patients who developed demyelinating polyradiculoneuropathy.
  • CASE PRESENTATION: A case report is presented of an unfortunate 53 year old Hispanic woman with acute myelogenous leukemia who developed profound weakness with cranial nerve palsies following both intravenous and intrathecal chemotherapy.
  • CONCLUSION: This is an interesting and unusual case of predominantly axonal ascending sensory motor polyradiculoneuropathy with cranial nerve involvement in an adult patient with acute myelogenous leukemia following intravenous Cytosine arabinoside and intrathecal methotrexate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):350-4 [17080338.001]
  • [Cites] J Infect Chemother. 2006 Jun;12(3):148-51 [16826348.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3110-6 [10506606.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):1899-905 [8909309.001]
  • [Cites] Muscle Nerve. 1995 Jun;18(6):636-48 [7753127.001]
  • [Cites] Bone Marrow Transplant. 1987 Aug;2(2):203-7 [3332167.001]
  • [Cites] Muscle Nerve. 2002 Jan;25(1):106-10 [11754193.001]
  • [Cites] Arch Phys Med Rehabil. 1988 Dec;69(12):1054-6 [3214264.001]
  • [Cites] Ann Neurol. 1990;27 Suppl:S7-12 [2194431.001]
  • [Cites] Cancer. 1982 Jul 1;50(1):42-7 [6177392.001]
  • [Cites] Cancer. 1976 Apr;37(4):1663-8 [946593.001]
  • [Cites] Med Princ Pract. 2003 Oct-Dec;12(4):272-5 [12966204.001]
  • [Cites] Neurol Clin. 2003 Feb;21(1):279-318, x [12690653.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):852-4 [3013396.001]
  • (PMID = 18937872.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2577643
  •  go-up   go-down


50. Sierra M, Alonso A, Odero MD, Gonzalez MB, Lahortiga I, Pérez JJ, García JL, Gutiérrez NC, Calasanz MJ, San Miguel JF, Hernández JM: Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain. Leuk Res; 2006 Aug;30(8):943-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain.
  • The incidence of chromosomal abnormalities in acute myeloid leukemia (AML) differs according to geographical regions in Spain.
  • We analyse 1,271 consecutive patients diagnosed of AML between 1995 and 2002 in three different regions of Spain: northern, central and southern.
  • By contrast, patients from the south of Spain showed lower incidence of t(8;21) (0%, compared to 1.6% and 3.6% in central and northern areas, respectively, p=0.04).
  • Trisomy 8 showed similar incidence in southern and central areas, while the incidence in the northern area was lower (14% and 10%, respectively, p=0.04).
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Genetics, Population. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503352.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


51. Grisendi S, Pandolfi PP: NPM mutations in acute myelogenous leukemia. N Engl J Med; 2005 Jan 20;352(3):291-2
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NPM mutations in acute myelogenous leukemia.
  • [MeSH-major] Cytoplasm. Leukemia, Myeloid, Acute / genetics. Mutation. Nuclear Proteins / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • (PMID = 15659732.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


52. Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips G 2nd, Abboud CN: Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res; 2007 Nov;31(11):1553-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.
  • Acute myelogenous leukaemia (AML) blasts transmigrate in response to SDF-1alpha.
  • AMD3100, a novel bicyclam molecule which inhibits stromal-derived factor (SDF)-1alpha/CXCR4 interactions, inhibited the transmigration of AML blasts and inhibited outgrowth of leukemia colony forming units.
  • AMD3100 did not abrogate stroma-mediated protection from cytarabine-mediated apoptosis, except in the case of one promyelocytic leukemic sample tested, and it did not influence adhesion of blasts to endothelial monolayers.
  • When AML blasts were pretreated with AMD3100, the positive effects of SDF-1alpha on NOD/SCID engraftment were diminished.
  • This work confirms that AML is influenced by the SDF-1alpha/CXCR4 axis and demonstrates that disruption of this axis by the bicyclam AMD3100 can influence AML microenvironmental interactions.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Leukoc Biol. 2004 Jul;76(1):185-94 [15075362.001]
  • [Cites] Blood. 2004 Jul 15;104(2):550-7 [15054042.001]
  • [Cites] Nat Med. 2004 Aug;10(8):858-64 [15235597.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1501-10 [15370200.001]
  • [Cites] Leukemia. 1994 Dec;8(12):2111-7 [7528857.001]
  • [Cites] Leukemia. 1996 Jun;10(6):1041-7 [8667639.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9448-53 [9689100.001]
  • [Cites] Science. 1999 Feb 5;283(5403):845-8 [9933168.001]
  • [Cites] Blood. 1999 May 15;93(10):3379-90 [10233890.001]
  • [Cites] Circulation. 2004 Nov 23;110(21):3300-5 [15533866.001]
  • [Cites] Leuk Res. 2005 Feb;29(2):185-96 [15607368.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3117-26 [15618475.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1307-18 [15837815.001]
  • [Cites] Stem Cells. 2005 Aug;23(7):879-94 [15888687.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1867-74 [15890685.001]
  • [Cites] Hematology. 2005 Dec;10(6):483-94 [16321813.001]
  • [Cites] Blood. 2001 Feb 1;97(3):799-804 [11157500.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2942-9 [15070669.001]
  • [Cites] Stem Cells. 2004;22(2):188-201 [14990858.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):52-7 [14757413.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Exp Hematol. 2001 Mar;29(3):345-55 [11274763.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Feb;10(1):81-93 [11276362.001]
  • [Cites] Exp Hematol. 2001 Apr;29(4):448-57 [11301185.001]
  • [Cites] Blood. 2001 May 15;97(10):3283-91 [11342460.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;938:26-34; discussion 34-5 [11458515.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1289-97 [11520773.001]
  • [Cites] Exp Hematol. 2001 Dec;29(12):1439-47 [11750103.001]
  • [Cites] Leukemia. 2002 Apr;16(4):650-7 [11960346.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1713-24 [12200686.001]
  • [Cites] FEBS Lett. 2002 Sep 11;527(1-3):255-62 [12220670.001]
  • [Cites] Exp Hematol. 2002 Sep;30(9):973-81 [12225788.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2778-86 [12351385.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1992-2003 [12357350.001]
  • [Cites] J Immunol. 2003 Jan 1;170(1):421-9 [12496427.001]
  • [Cites] J Clin Invest. 2003 Jan;111(2):187-96 [12531874.001]
  • [Cites] Glia. 2003 Apr 15;42(2):139-48 [12655598.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):581-7 [12815382.001]
  • [Cites] Leukemia. 2003 Jul;17(7):1294-300 [12835717.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2728-30 [12855591.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3136-46 [12869505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2900-7 [15070661.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1095-102 [15020611.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2981-9 [15070674.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2817-24 [15087398.001]
  • (PMID = 17403536.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112835-02; United States / NCI NIH HHS / CA / R21 CA112835; United States / NCI NIH HHS / CA / R21 CA112835-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Chemokine CXCL12; 0 / Culture Media; 0 / Heterocyclic Compounds; 155148-31-5 / JM 3100
  • [Other-IDs] NLM/ NIHMS34260; NLM/ PMC2133372
  •  go-up   go-down


53. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT: An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood; 2007 Dec 15;110(13):4427-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.
  • Leukemia stem cells (LSCs) are thought to play a central role in the pathogenesis of acute leukemia and likely contribute to both disease initiation and relapse.
  • These studies identified an analog, dimethylamino-parthenolide (DMAPT), which induces rapid death of primary human LSCs from both myeloid and lymphoid leukemias, and is also highly cytotoxic to bulk leukemic cell populations.
  • The compound has approximately 70% oral bioavailability, and pharmacologic studies using both mouse xenograft models and spontaneous acute canine leukemias demonstrate in vivo bioactivity as determined by functional assays and multiple biomarkers.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 27;1470(2):M55-62 [10722927.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2301-7 [11588023.001]
  • [Cites] Blood. 2002 Jan 1;99(1):319-25 [11756187.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16220-5 [12451177.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3142-9 [12468427.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):8992-9002 [14645512.001]
  • [Cites] Cancer Control. 2004 Mar-Apr;11(2):97-104 [15024346.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7178-87 [15378078.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2919-25 [15242869.001]
  • [Cites] Baillieres Clin Haematol. 1991 Jul;4(3):577-98 [1958881.001]
  • [Cites] J Exp Med. 1992 Jun 1;175(6):1501-9 [1375263.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2056-64 [10477735.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4163-9 [15687234.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):1004-12 [15956258.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6520-7 [16166428.001]
  • [Cites] Antioxid Redox Signal. 2006 Jan-Feb;8(1-2):99-106 [16487042.001]
  • [Cites] Cell Cycle. 2006 Sep;5(17):1940-5 [16940754.001]
  • [Cites] Chem Biol. 2007 Jul;14(7):813-23 [17656318.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2177-9 [11264190.001]
  • (PMID = 17804695.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090446; United States / NCI NIH HHS / CA / R01 CA90446
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Sesquiterpenes; 0 / Tumor Suppressor Protein p53; 2RDB26I5ZB / parthenolide
  • [Other-IDs] NLM/ PMC2234793
  •  go-up   go-down


54. Zhang YW, Wang SY, Lin X, Wang CY: [Identification of differentially expressed genes in familial acute myelogenous leukemia by suppression subtractive hybridization]. Zhonghua Yi Xue Za Zhi; 2007 Feb 27;87(8):533-7
Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of differentially expressed genes in familial acute myelogenous leukemia by suppression subtractive hybridization].
  • OBJECTIVE: To isolate genes expressed differentially from the bone marrow cells of patients with familial acute myelocytic leukemia and to explain the molecular mechanisms of the disease at the gene level.
  • METHODS: Bone marrow cells were obtained from a family with cases of familial acute myelocytic leukemia for successive 4 generations.
  • RESULTS: A subtractive library of differentially expressed genes for the family with cases of familial acute myelocytic leukemia was constructed successfully.
  • Some genes related to cell proliferation and differentiation has been acquired by SSH.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Leukemic. Leukemia, Myeloid / genetics. Nucleic Acid Hybridization / methods
  • [MeSH-minor] Acute Disease. Expressed Sequence Tags. Family Health. Female. Gene Library. Humans. Male. Molecular Sequence Data. Pedigree. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459202.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Databank-accession-numbers] GENBANK/ CV884199/ CV884202/ CV884203/ CV973096/ CV973097/ CV973098/ CV973099/ CV973100/ CV973101/ CX129926/ CX129927
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


55. Nakagawa M, Kameoka Y, Suzuki R: Nucleophosmin in acute myelogenous leukemia. N Engl J Med; 2005 Apr 28;352(17):1819-20; author reply 1819-20
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin in acute myelogenous leukemia.
  • [MeSH-major] Cytoplasm / chemistry. Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Active Transport, Cell Nucleus. Cell Nucleus / metabolism. Frameshift Mutation. Humans. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • (PMID = 15858195.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


56. Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H: Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood; 2007 Nov 15;110(10):3547-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
  • The rates of expected serious adverse events in patients with acute leukemia on chemotherapy far exceed those in patients with solid tumors.
  • To establish a baseline for expected toxicities before and during leukemia therapy, we reviewed 1534 adults with acute myeloid leukemia (AML; excluding acute promyelocytic leukemia) from 1990 to 2006 who received frontline intensive chemotherapy; 723 (47%) were 60 years or older.
  • This paper establishes a baseline toxicity rate for patients with AML during induction therapy, and this could be used as a control group for future reference.
  • Guidelines for reporting adverse events in leukemia studies should be revisited.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / standards. Leukemia, Myeloid, Acute / drug therapy. Neoadjuvant Therapy / adverse effects


57. Brioschi M, Fischer J, Cairoli R, Rossetti S, Pezzetti L, Nichelatti M, Turrini M, Corlazzoli F, Scarpati B, Morra E, Sacchi N, Beghini A: Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. Neoplasia; 2010 Nov;12(11):866-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.
  • Core-binding factor leukemia (CBFL) is a subgroup of acute myeloid leukemia (AML) characterized by genetic mutations involving the subunits of the core-binding factor (CBF).
  • The leukemogenesis model for CBFL posits that one, or more, gene mutations inducing increased cell proliferation and/or inhibition of apoptosis cooperate with CBF mutations for leukemia development.
  • A high expression of KIT is a hallmark of a high proportion of CBFL.
  • Here, we show that MIR-222/221 expression is upregulated after myeloid differentiation of normal bone marrow AC133(+) stem progenitor cells.
  • CBFL blasts with either t(8;21) or inv(16) CBF rearrangements with high expression levels of KIT (CD117) display a significantly lower level of MIR-222/221 expression than non-CBFL blasts.
  • Consistently, we found that the t(8;21) AML1-MTG8 fusion protein binds the MIR-222/221 promoter and induces transcriptional repression of a MIR-222/221-LUC reporter.
  • Because of the highly conserved sequence homology, we demonstrated concomitant MIR-222/221 down-regulation and KIT up-regulation in the 32D/WT1 mouse cell model carrying the AML1-MTG16 fusion protein.
  • This study provides the first hint that CBFL-associated fusion proteins may lead to up-regulation of the KIT receptor by down-regulating MIR-222/221, thus explaining the concomitant occurrence of CBF genetic rearrangements and overexpression of wild type or mutant KIT in AML.
  • [MeSH-major] Core Binding Factor alpha Subunits / genetics. Leukemia, Myeloid / genetics. MicroRNAs / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Animals. Antigens, CD / genetics. Antigens, CD / metabolism. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cell Line, Tumor. Cells, Cultured. Core Binding Factor Alpha 2 Subunit / genetics. Core Binding Factor Alpha 2 Subunit / metabolism. Down-Regulation. Erythropoietin / pharmacology. Female. Flow Cytometry. Glycoproteins / genetics. Glycoproteins / metabolism. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / metabolism. Humans. Male. Middle Aged. Mutation. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Peptides / genetics. Peptides / metabolism. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism. Reverse Transcriptase Polymerase Chain Reaction. U937 Cells

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] J Natl Cancer Inst. 2010 May 19;102(10):706-21 [20388878.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1369-75 [15855281.001]
  • [Cites] Oncogene. 2005 Aug 11;24(34):5325-32 [16007222.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Blood. 2000 Jan 15;95(2):726-7 [10660321.001]
  • [Cites] Nat Med. 2001 Apr;7(4):444-51 [11283671.001]
  • [Cites] Leukemia. 2001 Apr;15(4):664-5 [11368373.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403 [11526243.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1685-8 [11681407.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):63-74 [12086889.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):502-13 [12094236.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2449-56 [12239155.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6703-12 [12242670.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Feb;45(2):129-50 [12604126.001]
  • [Cites] Br J Haematol. 2003 Nov;123(4):749-50 [14616987.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Clin Chim Acta. 2004 May;343(1-2):85-92 [15115679.001]
  • [Cites] Genomics. 2004 Jul;84(1):1-9 [15203199.001]
  • [Cites] Haematologica. 2004 Aug;89(8):920-5 [15339674.001]
  • [Cites] Blood. 1990 Aug 15;76(4):801-7 [2200539.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6336-45 [8413232.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1603-11 [8123851.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):322-33 [9418879.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1924-33 [9490675.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4028-37 [9596646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • [Cites] Cell. 2005 Dec 2;123(5):819-31 [16325577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Blood. 2006 May 1;107(9):3463-8 [16384925.001]
  • [Cites] BMC Genomics. 2007;8:38 [17266773.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):457-66 [17996649.001]
  • [Cites] Leukemia. 2008 Feb;22(2):303-7 [17960171.001]
  • [Cites] Neoplasia. 2009 Feb;11(2):167-76 [19177201.001]
  • [Cites] BMC Bioinformatics. 2005;6:79 [15799782.001]
  • (PMID = 21076613.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / AML1-ETO fusion protein, human; 0 / Antigens, CD; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Core Binding Factor alpha Subunits; 0 / Glycoproteins; 0 / MIRN221 microRNA, human; 0 / MIRN222 microRNA, human; 0 / MicroRNAs; 0 / Oncogene Proteins, Fusion; 0 / Peptides; 11096-26-7 / Erythropoietin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2978910
  •  go-up   go-down


58. Oehadian A, Iqbal M, Sumantri R: Deep vein thrombosis in acute myelogenous leukemia. Acta Med Indones; 2009 Oct;41(4):200-4
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deep vein thrombosis in acute myelogenous leukemia.
  • Thrombotic complications in acute leukemia are often underestimated because bleeding complications generally dominate the clinical picture.
  • While there are many thrombogenic factors shared by both solid tumors and leukemia, many additional prothrombotic features are present in leukemia.
  • [MeSH-major] Leg / blood supply. Leukemia, Myeloid, Acute / complications. Venous Thrombosis / etiology


59. Sarafnejad A, Khosravi F, Alimoghadam K, Dianat S, Ansaripour B, Moradi B, Dorkhosh S, Amirzargar A: HLA class II allele and haplotype frequencies in iranian patients with acute myelogenous leukemia and control group. Iran J Allergy Asthma Immunol; 2006 Sep;5(3):115-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA class II allele and haplotype frequencies in iranian patients with acute myelogenous leukemia and control group.
  • We have analyzed HLA class II alleles and haplotypes in 60 Iranian patients with acute myelogenous leukemia (AML) and 180 unrelated normal subjects.
  • Significant positive association with the disease was found for HLA-DRB1*11 allele (35% vs. 24.7%, p=0.033).
  • It is suggested that HLA-DRB1*11 allele plays as a presumptive predisposing factor while the HLA-DRB4 and -DQB1*0303 alleles are suggested as protective genetic factors against acute myelogenous leukemia.
  • Larger studies are needed to confirm and establish the role of these associations with acute myelogenous leukemia.
  • [MeSH-major] HLA-DQ Antigens / genetics. HLA-DR Antigens / genetics. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Case-Control Studies. Gene Frequency. Genetic Predisposition to Disease. HLA-DQ alpha-Chains. HLA-DQ beta-Chains. Haplotypes. Humans. Iran / epidemiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237562.001).
  • [ISSN] 1735-1502
  • [Journal-full-title] Iranian journal of allergy, asthma, and immunology
  • [ISO-abbreviation] Iran J Allergy Asthma Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / HLA-DQ Antigens; 0 / HLA-DQ alpha-Chains; 0 / HLA-DQ beta-Chains; 0 / HLA-DQA1 antigen; 0 / HLA-DQB1 antigen; 0 / HLA-DR Antigens
  •  go-up   go-down


60. Abou-Jawde RM, Sobecks R, Pohlman B, Rybicki L, Advani A, Sekeres M, Kalaycio M: The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. Leuk Lymphoma; 2006 Apr;47(4):689-95
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of post-remission chemotherapy for older patients with acute myelogenous leukemia.
  • Standard practice in older patients with acute myeloid leukemia (AML) is induction chemotherapy (ICT) followed by post-remission chemotherapy (PRT).
  • We previously reported a median disease-free survival (DFS) and overall survival (OS) for patients in complete remission (CR) of 7.5 and 13.5 months, respectively, in 30 older patients treated with standard ICT and PRT (study A).
  • Forty patients with AML age > or =60 years were treated with ICT consisting of standard dose cytosine arabinoside and mitoxantrone followed with granulocyte-macrophage colony-stimulating factor subcutaneously starting day 11 if the bone marrow aspirate and biopsy was hypocellular.
  • Myelodysplasia preceded AML in 37% of patients.
  • However, DFS and OS did not differ significantly between patients treated in study A or study B (P = 0.21 and P = 0.15, respectively).
  • PRT has not clearly improved survival in older patients with AML, and therefore the routine addition of chemotherapy to older patients in complete remission is not indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / pathology. Mitoxantrone / administration & dosage

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Apr;47(4):579-80 [16886271.001]
  • (PMID = 16690528.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


61. Thomas X, Dombret H: Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia. Hematology; 2007 Feb;12(1):15-28
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.
  • Increasing the intensity of induction chemotherapy has generated considerable recent interest in the treatment of acute myeloid leukemia.
  • Achieving complete remission is a sine qua non condition for prolonged disease-free survival and may affect long-term outcome.
  • Whether these results are due to the biologic recruitment of cell cycle-specific agents is unknown.
  • Here we review the results of timed-sequential chemotherapy, used as induction regimen in de novo, relapsed or refractory AML or used as post-remission therapy, and compare them with those from other types of regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Animals. Antimetabolites, Antineoplastic / administration & dosage. Bone Marrow Diseases / chemically induced. Cell Cycle / drug effects. Child. Cytarabine / pharmacology. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Flavonoids / administration & dosage. Flavonoids / pharmacology. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / pharmacology. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Middle Aged. Piperidines / administration & dosage. Piperidines / pharmacology. Premedication. Prognosis. Rats. Remission Induction / methods. Retrospective Studies. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364988.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 45AD6X575G / alvocidib; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 127
  •  go-up   go-down


62. Liu H, Qian WB, Mai WY, Meng HT, Tong HY, Tong Y, Mao LP, Huang J, Wang L, Jiang DZ, Jin J: [HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jan;29(1):9-12
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].
  • OBJECTIVE: To analyse the outcome of newly diagnosed adult acute myeloid leukemia (AML) patients treated with HAA (homoharringtonine, cytarabine and aclarubicin) regimen and explore the efficacy and safety of this regimen.
  • Kaplan-Meier method was used to estimate relapse free survival (RFS) rate and the differences were compared with 2-sided log-rank test.
  • For the AML-M5 and AML-M /M2 patients the CR rate was 74% and 87% and 3 year RFS of CR patients was 75% and 37%, respectively.
  • CONCLUSION: HAA regimen is a safe, efficacious, and well-tolerable induction therapy for newly diagnosed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18512308.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Harringtonines; 04079A1RDZ / Cytarabine; 6FG8041S5B / homoharringtonine; 74KXF8I502 / Aclarubicin
  •  go-up   go-down


63. AbuTarif MA, Krishna G, Statkevich P: Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin; 2010 Feb;26(2):397-405
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
  • These covariates did not predominate in patients who developed IFI.
  • However, because of the successful prophylaxis and the low number of posaconazole-treated patients with IFI proven or probable (IFIPP), the absence of a statistically significant relationship between IFIPP and exposure may not mean this relationship does not exist.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Mycoses / prevention & control. Myelodysplastic Syndromes / drug therapy. Neutropenia / chemically induced. Triazoles / pharmacokinetics


64. Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R, Chiang JH, Hood L, Clarke MF, Weissman IL: Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A; 2009 Mar 3;106(9):3396-401
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysregulated gene expression networks in human acute myelogenous leukemia stem cells.
  • We performed the first genome-wide expression analysis directly comparing the expression profile of highly enriched normal human hematopoietic stem cells (HSC) and leukemic stem cells (LSC) from patients with acute myeloid leukemia (AML).
  • Several pathways, including Wnt signaling, MAP Kinase signaling, and Adherens Junction, are well known for their role in cancer development and stem cell biology.
  • Other pathways have not been previously implicated in the regulation of cancer stem cell functions, including Ribosome and T Cell Receptor Signaling pathway.
  • This study demonstrates that combining global gene expression analysis with detailed annotated pathway resources applied to highly enriched normal and malignant stem cell populations, can yield an understanding of the critical pathways regulating cancer stem cells.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6 [10861016.001]
  • [Cites] Nat Med. 2007 Jan;13(1):78-83 [17159988.001]
  • [Cites] Exp Hematol. 2000 Jul;28(7):858-70 [10907648.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):198-201 [11175634.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2301-7 [11588023.001]
  • [Cites] Blood. 2002 Jan 15;99(2):488-98 [11781229.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(12):680-7 [11787531.001]
  • [Cites] Science. 2002 Oct 18;298(5593):601-4 [12228721.001]
  • [Cites] Annu Rev Immunol. 2003;21:759-806 [12615892.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Nature. 2003 May 22;423(6938):448-52 [12717451.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):836-41 [14574412.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):841-6 [14574413.001]
  • [Cites] Genome Res. 2003 Nov;13(11):2498-504 [14597658.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Cell. 2004 Jul 23;118(2):149-61 [15260986.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2804-8 [1372992.001]
  • [Cites] J Exp Med. 1993 May 1;177(5):1331-42 [7683034.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Blood. 1995 Jan 15;85(2):368-78 [7529060.001]
  • [Cites] Blood. 1997 May 1;89(9):3104-12 [9129012.001]
  • [Cites] Blood. 2007 Oct 15;110(8):3005-14 [17616640.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3334-44 [17638851.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10296-303 [17974971.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):8-20 [17910043.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5320-5 [9144235.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Leuk Res. 2005 Jun;29(6):653-9 [15863205.001]
  • [Cites] Blood. 2005 Aug 1;106(3):903-5 [15831702.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6296-305 [16155012.001]
  • [Cites] PLoS Genet. 2005 Sep;1(3):e28 [16151515.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1111-5 [16564000.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2463-72 [16760446.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1203-11 [16956819.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2147-54 [17039238.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(3):262-71 [10871151.001]
  • (PMID = 19218430.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P01 DK053074; United States / NCI NIH HHS / CA / 5K08CA100138; United States / NIDDK NIH HHS / DK / P01DK53074; United States / NCI NIH HHS / CA / R01 CA086017; United States / NCI NIH HHS / CA / R01CA86017; United States / NCI NIH HHS / CA / K08 CA100138; United States / NCI NIH HHS / CA / P01 CA139490; None / None / / P01 CA139490-03; United States / NCI NIH HHS / CA / P01 CA139490-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2642659
  •  go-up   go-down


65. Shao B, Gao YR, Wang C, Yan SK, Cai Q, Jiang JL, Yang J, Bai HT, Zhao M, Zhao CX: [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia]. Ai Zheng; 2006 Aug;25(8):1007-12
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
  • BACKGROUND & OBJECTIVE: The manifestations of old acute myelogenous (AML) patients have their special biological and clinical characteristics, with lower response rate to therapy and shorter survival time.
  • This study was to investigate the prognostic factors of elderly patients with AML retrospectively.
  • METHODS: 77 patients aged> or =60 years with AML from 1994 to 2005 were admitted to our study and all the possible prognostic factors were analyzed with Kaplan-Meier survival analysis.
  • The patients with primary AML (median survival time was 98 days) had significantly longer survival time than those with secondary AML (median survival time was 32 days)(P=0.007), which their CR ratios were 50% and 0% (P=0.023).
  • The patients with bone marrow blast cell ratio< or =50% (median survival time was 98 days ) had significantly longer survival time than those with bone marrow blast cell ratio >50% (median survival time was 55 days)(P=0.006).
  • The patients with the peripheral blood white blood cell count (PBWBC)>10x10(9)/L (50%) had significantly higher CR ratio than those with PBWBC< or =10x10(9)/L (25%)(P=0.043).
  • CONCLUSIONS: Factors, including age >70, PS 2 to 4, percentage of blasts in bone marrow >50%, secondary AML, unfavorable karyotype, expression of CD34, lower dosage.
  • [MeSH-major] Anthracyclines / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965684.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antigens, CD34
  •  go-up   go-down


66. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT: The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood; 2005 Jun 1;105(11):4163-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.
  • Recent studies have described malignant stem cells as central to the initiation, growth, and potential relapse of acute and chronic myelogenous leukemia (AML and CML).
  • Because of their important role in pathogenesis, rare and biologically distinct leukemia stem cells (LSCs) represent a critical target for therapeutic intervention.
  • The present studies demonstrate that parthenolide (PTL), a naturally occurring small molecule, induces robust apoptosis in primary human AML cells and blast crisis CML (bcCML) cells while sparing normal hematopoietic cells.
  • Furthermore, analysis of progenitor cells using in vitro colony assays, as well as stem cells using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) xenograft model, show that PTL also preferentially targets AML progenitor and stem cell populations.
  • Notably, in comparison to the standard chemotherapy drug cytosine arabinoside (Ara-C), PTL is much more specific to leukemia cells.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4912-8 [15256463.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] FEBS Lett. 1997 Jan 27;402(1):85-90 [9013864.001]
  • [Cites] Blood. 1997 May 1;89(9):3104-12 [9129012.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4325-35 [9834239.001]
  • [Cites] Planta Med. 1999 Mar;65(2):126-9 [10193202.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2191-9 [15256485.001]
  • [Cites] Nat Prod Rep. 1995 Jun;12(3):271-6 [7792073.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5617-23 [10553091.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):329-33 [10623619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4844-9 [10781090.001]
  • [Cites] Exp Hematol. 2000 Jun;28(6):660-71 [10880752.001]
  • [Cites] Gene Ther. 2000 Jul;7(14):1234-7 [10918492.001]
  • [Cites] Oncogene. 2000 Aug 24;19(36):4159-69 [10962577.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2177-9 [11264190.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12076-83 [11278531.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):759-66 [11514225.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 21;287(2):522-9 [11554760.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2301-7 [11588023.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):39713-20 [11500489.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7367-72 [12032289.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38954-64 [12151389.001]
  • [Cites] J Lipid Res. 2002 Nov;43(11):1818-28 [12401880.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16220-5 [12451177.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3142-9 [12468427.001]
  • [Cites] Exp Mol Med. 2003 Aug 31;35(4):290-300 [14508070.001]
  • [Cites] J Dent Res. 2003 Oct;82(10):802-6 [14514760.001]
  • [Cites] Lab Invest. 2003 Oct;83(10):1529-39 [14563954.001]
  • [Cites] Cancer Control. 2004 Mar-Apr;11(2):97-104 [15024346.001]
  • [Cites] Invest New Drugs. 2004 Aug;22(3):299-305 [15122077.001]
  • [Cites] Cancer Lett. 2004 May 28;208(2):143-53 [15142672.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):885-90 [15151944.001]
  • [Cites] Life Sci. 2004 Jul 2;75(7):841-56 [15183076.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7330-44 [15286701.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1699-704 [15343345.001]
  • [Cites] J Pharm Sci. 1973 Feb;62(2):345 [4686424.001]
  • [Cites] Mol Pharmacol. 1981 Jan;19(1):97-102 [7207466.001]
  • [Cites] J Exp Med. 1992 Jun 1;175(6):1501-9 [1375263.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1449-58 [15033901.001]
  • (PMID = 15687234.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA90446
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lactones; 0 / NF-kappa B; 0 / Reactive Oxygen Species; 0 / Sesquiterpenes; 0 / Tumor Suppressor Protein p53; 2RDB26I5ZB / parthenolide
  • [Other-IDs] NLM/ PMC1895029
  •  go-up   go-down


67. Dawczynski K, Steinbach D, Wittig S, Pfaffendorf N, Kauf E, Zintl F: Expression of components of the IGF axis in childhood acute myelogenous leukemia. Pediatr Blood Cancer; 2008 Jan;50(1):24-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of components of the IGF axis in childhood acute myelogenous leukemia.
  • PROCEDURE: We analyzed the mRNA expression profile of IGF-I, -II, and IGFBP-2, -3 in 50 children with previously untreated AML (mean age 10.8 +/- 4.8 years; patients in CCR n = 20, patients with relapse during later course of disease n = 15).
  • RESULTS: IGFBP-2 expression was significantly higher in AML cells than in healthy cells of peripheral MNC (P < 0.001) and of bone marrow cells (P < 0.01).
  • Conversely, AML cells showed significantly lower IGFBP-3 and IGF-I gene expression compared to controls (P = 0.02; P < 0.001).
  • Patients with relapse (median +/- range: 0.0929 +/- 0.049) during later course of disease demonstrated higher IGFBP-2 expression compared to patients in CCR (0.0121 +/- 0.047; P = 0.06) at time of diagnosis.
  • Furthermore, the probability of relapse-free survival (RFS) in patients with IGFBP-2 mRNA level >0.1000 was 28%; whereas, the probability of RFS in patients with IGFBP-2 mRNA level <0.1000 was 62% (P = 0.04, log-rank test).
  • CONCLUSIONS: Results identified different expressions of IGF components between normal and AML cells.
  • Patients with IGFBP-2 mRNA levels up to 0.1000 (relative to KG1 cell line) more likely developed a relapse.
  • Identification of these patients at diagnosis may allow more individualized treatment.
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 2 / metabolism. Insulin-Like Growth Factor Binding Protein 3 / metabolism. Insulin-Like Growth Factor I / metabolism. Insulin-Like Growth Factor II / metabolism. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Child. Disease-Free Survival. Gene Expression. Humans. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17635002.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / RNA, Messenger; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


68. Ravandi Kashani F, Cortes J, Faderl S, Jones D, Byrd A, Brandt M, Garcia-Manero G, Levis M, Andreeff M, Kantarjian H: Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML).
  • It selectively induces apoptosis in FLT3-mutant human AML cell lines at nM concentrations.
  • METHODS: Objectives of this study are to determine the tolerability and efficacy of combination of S with chemotherapy.
  • In the phase I part, pts with relapsed AML were treated with escalating doses of S (400 mg qod, 400 mg daily, 400 mg bid) for 7 days during induction, and 400 mg bid was established as safe.
  • RESULTS: 10 pts (median age 34, range 21-58) with relapsed AML (median prior therapy 2, range 1-6) were treated in the phase I .
  • 5 pts have relapsed; median CR duration has not been reached, (range; 0.2+ - 10.6+ mo).
  • CONCLUSIONS: S can be safely combined with IA; it has a high CR rate in frontline therapy of younger pts with AML, in particular those with FLT3 mutations.
  • Correlative studies confirm potent activity of S against FLT3 signaling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Kirkeleit J, Riise T, Bråtveit M, Moen BE: Increased risk of acute myelogenous leukemia and multiple myeloma in a historical cohort of upstream petroleum workers exposed to crude oil. Cancer Causes Control; 2008 Feb;19(1):13-23
Hazardous Substances Data Bank. BENZENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of acute myelogenous leukemia and multiple myeloma in a historical cohort of upstream petroleum workers exposed to crude oil.
  • Benzene exposure has been shown to be related to acute myelogenous leukemia, while the association with multiple myeloma and non-Hodgkin lymphoma has been a much-debated issue.
  • Workers in the job category "upstream operator offshore", having the most extensive contact with crude oil, had an excess risk of hematologic neoplasms (blood and bone marrow) (rate ratio (RR) 1.90, 95% confidence interval (95% CI): 1.19-3.02).
  • This was ascribed to an increased risk of acute myelogenous leukemia (RR 2.89, 95% CI: 1.25-6.67) and multiple myeloma (RR 2.49, 95% CI: 1.21-5.13).
  • There were no statistical differences between the groups in respect to non-Hodgkin lymphoma.
  • The results suggest that benzene exposure, which most probably caused the increased risk of acute myelogenous leukemia, also resulted in an increased risk of multiple myeloma.
  • [MeSH-major] Leukemia, Myeloid, Acute / chemically induced. Multiple Myeloma / chemically induced. Occupational Diseases / chemically induced. Petroleum / adverse effects


70. Bhatia N, Wallace T, Divgi A, Short V: Myeloid sarcoma presenting as an isolated nodule in a patient with acute myelogenous leukemia. J Drugs Dermatol; 2007 Apr;6(4):447-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma presenting as an isolated nodule in a patient with acute myelogenous leukemia.
  • We report a case of an elderly female in remission from acute myelogenous leukemia that presented with a nonhealing enlarging asymptomatic nodule on her right thigh.
  • A wide excision of the nodule and histological examination revealed myeloid sarcoma without evidence or overlap of leukemia cutis, which had been suspected from nodules that had developed early in the course of the disease.
  • The patient subsequently underwent radiation therapy to the area with sustained clearance.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Sarcoma, Myeloid / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Acute Disease. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Radiotherapy. Treatment Outcome


71. Samanta DR, Senapati SN, Sharma PK, Mohanty A, Samantaray S: Acute myelogenous leukemia following treatment of invasive cervix carcinoma: a case report and a review of the literature. J Cancer Res Ther; 2009 Oct-Dec;5(4):302-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia following treatment of invasive cervix carcinoma: a case report and a review of the literature.
  • Here is a case report on acute myelogenous leukemia, which developed after 63 months following the completion of treatment with surgery and platinum-based chemoradiation in a patient of carcinoma cervix IB.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Leukemia, Myeloid, Acute / etiology. Neoplasms, Second Primary / pathology. Uterine Cervical Neoplasms / therapy


72. Henrich TJ, Marty FM, Milner DA Jr, Thorner AR: Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. Transpl Infect Dis; 2009 Oct;11(5):458-62
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature.
  • We describe a woman with relapsed acute myelogenous leukemia after allogeneic stem cell transplantation who developed disseminated Geotrichum candidum infection during chemotherapy-induced neutropenia.
  • [MeSH-major] Geotrichosis / microbiology. Geotrichum. Leukemia, Myeloid, Acute / complications. Stem Cell Transplantation / adverse effects. Transplantation, Homologous / adverse effects

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804480.001).
  • [ISSN] 1399-3062
  • [Journal-full-title] Transplant infectious disease : an official journal of the Transplantation Society
  • [ISO-abbreviation] Transpl Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 12
  •  go-up   go-down


73. Jabbour E, Faderl S, Ravandi F, Konopleva M, Verstovsek S, Cortes J, Wierda W, Newsome WM, Yang H, Kantarjian H, Garcia-Manero G: Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML).
  • : 7004 Background: Standard induction therapy for pts with AML has not changed over the last 2 decades nor has the outcome of these pts.
  • We designed a phase II study of V with IA as front-line therapy for MDS/AML.
  • METHODS: Pts with untreated int-2/high-risk MDS or AML ages 15-65 with adequate liver and renal functions and PS, and EF ≥ 50% were eligible.
  • 3 pts with relapsed/refractory AML were treated in the run-in phase.
  • 8 (47%) had secondary disease.
  • The median PFS has not been reached.
  • CONCLUSIONS: The combination of IA and V is safe and active in AML/MDS.
  • Results will be compared with those of a parallel IA study at MDACC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961376.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Aguilera SB, Zarraga M, Rosen L: Leukemia cutis in a patient with acute myelogenous leukemia: a case report and review of the literature. Cutis; 2010 Jan;85(1):31-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis in a patient with acute myelogenous leukemia: a case report and review of the literature.
  • Leukemia cutis is an infiltration of malignant neoplastic leukocytes or their precursors into the epidermis, dermis, or subcutis.
  • Acute myelogenous leukemia (AML) is the second most common cause of leukemia cutis and the most common leukemia among adults.
  • In the elderly population, AML presents a challenge to the medical community because of the number of preexisting comorbid conditions and the safety profile of useful chemotherapeutic agents.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemic Infiltration. Skin / pathology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184209.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Iwen PC, Freifeld AG, Sigler L, Tarantolo SR: Molecular identification of Rhizomucor pusillus as a cause of sinus-orbital zygomycosis in a patient with acute myelogenous leukemia. J Clin Microbiol; 2005 Nov;43(11):5819-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular identification of Rhizomucor pusillus as a cause of sinus-orbital zygomycosis in a patient with acute myelogenous leukemia.
  • Sinus-orbital zygomycosis caused by Rhizomucor pusillus in a patient with acute myelogenous leukemia is described.
  • This report highlights the value of ITS sequencing as a diagnostic tool for the identification of R. pusillus and expands the understanding of infection types caused by this zygomycete.
  • [MeSH-major] Frontal Sinusitis / diagnosis. Leukemia, Myeloid, Acute / complications. Mucormycosis / diagnosis. Orbital Diseases / diagnosis. Rhizomucor / isolation & purification

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Zygomycosis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 1999 Dec;37(12):3957-64 [10565914.001]
  • [Cites] J Clin Microbiol. 2005 May;43(5):2092-103 [15872227.001]
  • [Cites] Clin Microbiol Rev. 2000 Apr;13(2):236-301 [10756000.001]
  • [Cites] Scand J Infect Dis. 2001;33(4):316-9 [11345227.001]
  • [Cites] Mycoses. 2001;44(7-8):253-60 [11714058.001]
  • [Cites] Med Mycol. 2002 Feb;40(1):87-109 [11860017.001]
  • [Cites] Leuk Lymphoma. 2001 Nov-Dec;42(6):1393-9 [11911424.001]
  • [Cites] Diabetes Res Clin Pract. 2002 Aug;57(2):139-42 [12062859.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):465-84 [12097252.001]
  • [Cites] Mykosen. 1972 Jan 1;15(1):11-7 [5059257.001]
  • [Cites] JAMA. 1972 Nov 20;222(8):951-3 [4120332.001]
  • [Cites] JAMA. 1973 Aug 13;225(7):737-8 [4515739.001]
  • [Cites] Arch Dermatol. 1977 Aug;113(8):1075-6 [268159.001]
  • [Cites] Pediatr Infect Dis. 1982 Mar-Apr;1(2):110-4 [6960330.001]
  • [Cites] J Hosp Infect. 1983 Mar;4(1):45-9 [6190884.001]
  • [Cites] South Med J. 1989 Nov;82(11):1432-4 [2814631.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Mycopathologia. 1991 Feb;113(2):79-80 [2034262.001]
  • [Cites] Clin Infect Dis. 1993 May;16(5):640-5 [8507755.001]
  • [Cites] J Clin Microbiol. 1995 Mar;33(3):781-3 [7751398.001]
  • [Cites] Am J Kidney Dis. 1997 Mar;29(3):461-4 [9041226.001]
  • [Cites] J Clin Microbiol. 1998 Jul;36(7):2153-6 [9650990.001]
  • [Cites] J Clin Microbiol. 2004 Nov;42(11):5400-2 [15528755.001]
  • [Cites] J Clin Microbiol. 2005 Mar;43(3):1456-8 [15750132.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1350-60 [15776383.001]
  • [Cites] J Clin Microbiol. 2000 Apr;38(4):1510-5 [10747135.001]
  • (PMID = 16272531.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF461764
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Fungal; 0 / DNA, Ribosomal Spacer
  • [Other-IDs] NLM/ PMC1287840
  •  go-up   go-down


76. Mullally A, Ebert BL: NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Clin Cancer Res; 2010 Aug 15;16(16):4074-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF1 inactivation revs up Ras in adult acute myelogenous leukemia.
  • Mutations in the Ras pathway are common in myeloid malignancies.
  • NF1, a tumor suppressor and negative regulator of Ras, is inactivated in a subset of adult acute myelogenous leukemia (AML) cases.
  • Loss of NF1 function sensitizes cells to inhibition of mammalian target of rapamycin (mTOR), a downstream effector of Ras activation, highlighting a potential therapeutic opportunity for some AML patients.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Genes, Neurofibromatosis 1. Leukemia, Myeloid, Acute / genetics. Signal Transduction / genetics. ras Proteins / biosynthesis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2010 Aug 15;16(16):4135-47 [20505189.001]
  • (PMID = 20587590.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


77. Ubukata H, Katano M, Takemura A, Kasuga T, Motohashi G, Ge L, Tabuchi T: Acute myelogenous leukemia suddenly developing just after surgery for advanced gastric cancer: report of a case. Surg Today; 2005;35(2):153-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia suddenly developing just after surgery for advanced gastric cancer: report of a case.
  • We report a case of acute myelogenous leukemia (AML) developing just after surgery for advanced gastric cancer, before adjuvant chemotherapy was started.
  • Acute myelogenous leukemia was diagnosed by an aspiration biopsy of the bone marrow.
  • If the AML had developed later and had become remarkable during or after adjuvant chemotherapy, the differential diagnosis between de novo and therapy-related leukemia would have been very difficult.
  • Most leukemias that develop during the course of chemotherapy or radiotherapy, or both, are indisputably considered to be therapy-related.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary / diagnosis. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Bone Marrow Cells / pathology. Humans. Male. Postoperative Complications / diagnosis


78. Kunivayalil S, Jain A, Satheesh C, Tejinder S, Lakshmaiah K, Suresh TM, Lokanatha D, Babu G: A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e18005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia.
  • It can be used during induction and consolidation chemotherapy in acute myeloid leukemia (AML).
  • Few studies addressed the use of pegylated filgrasim in AML.
  • Safety profile and complete remission status did not differ between the two groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964003.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Zhang JH, Zheng YC, Wang YX, Zhang JY, Liu ZG: Enlarged and prominent nucleus may be indicative of tetraploidy: a laboratory study of a rare near-tetraploidy in a child patient with acute myelogenous leukemia AML-M4. J Pediatr Hematol Oncol; 2010 Jan;32(1):19-21
Genetic Alliance. consumer health - Tetraploidy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enlarged and prominent nucleus may be indicative of tetraploidy: a laboratory study of a rare near-tetraploidy in a child patient with acute myelogenous leukemia AML-M4.
  • SUMMARY: Near-tetraploidy is a rare cytogenetic abnormality in myelocytic malignancies in children and its significance is unknown.
  • To investigate the pathologic characteristics of a near-tetraploidy in a child with acute myelogenous leukemia (AML-M4), bone marrow smears were prepared for morphologic analysis.
  • Combined with morphologic and immunophenotypic results, the diagnosis was established as acute myelogenous leukemia (AML-M4).
  • Near-tetraploidy is an uncommon cytogenetic finding, and the experience of this case further emphasizes the importance of the laboratory diagnostic methods.
  • [MeSH-major] Cell Nucleus / pathology. Leukemia, Myelomonocytic, Acute / diagnosis. Leukemia, Myelomonocytic, Acute / genetics. Polyploidy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19816206.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Sarvis JA, Auge BK: Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia. Urology; 2009 May;73(5):1163.e1-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia.
  • Myeloid sarcoma involving the genitourinary system is a rare complication associated with acute myelogenous leukemia or other myeloproliferative disorders.
  • The diagnosis is made by pathologic findings of diffuse infiltration of intermediate-size neoplastic cells and fibrosis of the affected organ.
  • We report the second known case of myeloid sarcoma involving the epididymis in a patient with a history of acute myelogenous leukemia.
  • [MeSH-major] Epididymis / pathology. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Marrow Transplantation / methods. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Recurrence. Risk Assessment. Transplantation, Homologous. Treatment Outcome. Ultrasonography, Doppler


81. Thomas X: The role of timed sequential chemotherapy in adult acute myelogenous leukemia. Curr Hematol Malig Rep; 2008 Apr;3(2):89-95
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of timed sequential chemotherapy in adult acute myelogenous leukemia.
  • Consecutive trials of timed sequential chemotherapy (TSC) have been conducted in adults with acute myelogenous leukemia.
  • The rationale for TSC was based on the observation that leukemic cells can be recruited synchronously into the cell cycle after initial intensive therapy, at which time they may become more susceptible to killing by chemotherapeutic agents.
  • Achieving complete remission is essential for prolonged disease-free survival and may affect long-term outcome.
  • This article reviews the results of important trials in which TSC was used as an induction regimen in de novo, relapsed, or refractory acute myelogenous leukemia or as postremission therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Cell Cycle / drug effects. Clinical Trials as Topic. Drug Administration Schedule. Humans

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425452.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


82. Foss B, Tronstad KJ, Bruserud Ø: Connexin-based signaling in acute myelogenous leukemia (AML). Biochim Biophys Acta; 2010 Jan;1798(1):1-8
Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connexin-based signaling in acute myelogenous leukemia (AML).
  • Normal and malignant hematopoiesis are regulated by intercellular communication in the hematopoietic microenvironments, and both soluble mediators as well as direct cell-cell contact play important functional roles.
  • Gap junctions are complex membrane structures that transfer molecules between neighboring cells and thereby alter intracellular signaling and metabolism.
  • Connexins are furthermore involved in cell regulation as single molecules by modulating intracellular pathways and possibly gene transcription.
  • The role of connexins in leukemogenesis and leukemic cell functions are not well characterized.
  • In this review, we describe the known effects of gap junctions and connexins in acute myelogenous leukemia and the diverse potential of connexins in acute myelogenous leukemia chemosensitivity, intracellular signaling and cell death regulation.
  • [MeSH-major] Connexins / metabolism. Leukemia, Myeloid / metabolism. Signal Transduction
  • [MeSH-minor] Acute Disease. Apoptosis. Cell Communication. Gap Junctions / metabolism. Humans. Models, Biological

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883623.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Connexins
  • [Number-of-references] 103
  •  go-up   go-down


83. Steensma D, Kantarjian H, Wijermans P: Clinical experience with different dosing schedules of decitabine in patients with myelodysplastic syndromes (MDS). J Clin Oncol; 2009 May 20;27(15_suppl):7011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data from each clinical trial supporting overall improvement, duration of improvement, time to AML or death, progression-free survival (PFS), and transfusion independence was assessed.
  • RESULTS: Patients had IPSS classification scores of intermediate-2 or high-risk (D-0007, 70%; EORTC-06011, 93%; ID03-0180, 66%; DACO-020, 46%) and de novo MDS (D-0007, 87%; EORTC-06011, 88%; ID03-0180, 70%; DACO-020, 89%).
  • Comparable overall improvement (complete response [CR] + partial response [PR] + hematologic improvement [HI]), time to AML or death, and PFS was observed across all trials (Table).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961372.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Erba HP, Kantarjian HM, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Faderl S: Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s). J Clin Oncol; 2009 May 20;27(15_suppl):7062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).
  • We now report updated duration of remission (DOR), disease-free survival (DFS), and overall survival (OS).
  • METHODS: Single arm, multi-center, phase II, open-label, 2-stage study of patients with untreated AML, ≥60 years old, and at least one adverse prognostic factor: age ≥70 years, antecedent hematologic disorder (AHD), PS = 2, and/or intermediate/unfavorable risk karyotype.
  • Clofarabine (CLO) administered days 1-5 at 30 mg/m<sup>2</sup> during induction and 20 mg/m<sup>2</sup> during re-induction/consolidation for maximum 6 cycles.
  • Median DOR (censored at alternative therapy) for CR/CRp was 56 weeks (95% CI, 33 weeks - not yet estimable [n/e]) and for CR 65 weeks (95% CI, 41 weeks - n/e).
  • Median DFS (not censored at alternative therapy) for CR/CRp was 34 weeks (95% CI, 24 - 65 weeks).
  • CONCLUSIONS: These data expand on the previously reported efficacy and safety data of single agent CLO in adult AML.
  • These results suggest that single agent CLO is an effective and tolerable treatment option for older adult patients with untreated AML and 1 or more unfavorable baseline prognostic factor(s).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Kurt M, Shorbagi A, Altundag K, Elkiran T, Güllü I, Kansu E: Possible association between Budd-Chiari Syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia. Am J Hematol; 2005 Nov;80(3):213-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible association between Budd-Chiari Syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia.
  • Gemtuzumab ozogamicin (GO; CMA-676; Mylotarg) is a chemotherapeutic agent approved for the treatment of CD33-positive acute myelogenous leukemia in patients of age 60 years or older after first relapse.
  • Hepatic veno-occlusive disease has been reported to develop as a late complication of gemtuzumab ozogamicin treatment.
  • This complication has not been previously reported, and it deserves to be considered as a possible adverse effect of gemtuzumab ozogamicin.
  • [MeSH-major] Aminoglycosides / adverse effects. Antibodies, Monoclonal / adverse effects. Budd-Chiari Syndrome / chemically induced. Leukemia, Myeloid, Acute / complications

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Budd-Chiari Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247755.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab
  •  go-up   go-down


86. Blaser BW, Gonit M, Qi H, Shatnawi A, Guimond M, Lee RJ, Ratnam M: Induction of folate receptor type beta in a bone marrow engraftment model of acute myelogenous leukemia. Leukemia; 2007 Oct;21(10):2233-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of folate receptor type beta in a bone marrow engraftment model of acute myelogenous leukemia.
  • [MeSH-major] Bone Marrow Cells / cytology. Carrier Proteins / metabolism. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Cells, Cultured. Folate Receptors, GPI-Anchored. Humans. Inflammation. Mice. Mice, Inbred NOD. Mice, SCID. RNA, Messenger / metabolism. Stem Cells / metabolism

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554378.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095673; United States / NCI NIH HHS / CA / R01 CA080183
  • [Publication-type] Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / RNA, Messenger; 0 / Receptors, Cell Surface
  •  go-up   go-down


87. Fujita A, Fujisawa S, Hyo R, Kuwabara H, Yamazaki E, Tomita N, Ishigatsubo Y: [Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia]. Rinsho Ketsueki; 2008 Jan;49(1):51-4
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia].
  • A 42-year-old woman was admitted to our hospital with acute myelogenous leukemia.
  • We should be aware that blood group antigens are not entirely independent of the environment and are occasionally modified by disease.
  • [MeSH-major] ABO Blood-Group System / immunology. Blood Grouping and Crossmatching. Leukemia, Myeloid, Acute / blood

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277597.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


88. Quintás-Cardama A, Abruzzo LV, Giles FJ, Jorgensen J, Cortes J, Sarriera JE, Kantarjian H, Verstovsek S: A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome. Leukemia; 2006 Sep;20(9):1638-40
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic


89. Miyamoto T: [Autologous peripheral blood stem cell transplantation as a treatment choice for adult acute myelogenous leukemia]. Rinsho Ketsueki; 2010 Jul;51(7):477-83
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous peripheral blood stem cell transplantation as a treatment choice for adult acute myelogenous leukemia].
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693766.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


90. Sada E, Henzan H, Ohtani R, Takase K, Miyamoto T, Fukuda T, Nagafuji K, Yamauchi K, Takamatsu Y, Inaba S, Harada M: Conditioning with targeted busulfan for autologous peripheral blood stem cells transplantation for acute myelogenous leukemia in an XYY male. Am J Hematol; 2005 Jan;78(1):55-8
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditioning with targeted busulfan for autologous peripheral blood stem cells transplantation for acute myelogenous leukemia in an XYY male.
  • We report herein a 19-year-old Japanese male with XYY syndrome who developed acute myelogenous leukemia.
  • The patient was treated with granulocyte colony-stimulating factor combined with etoposide, cytarabine, and busulfan (the latter adjusted to a targeting dose) followed by autologous peripheral blood stem cell transplantation.
  • He had no severe regimen-related toxicities and is now free of leukemia.
  • [MeSH-major] Busulfan / administration & dosage. Immunosuppressive Agents / administration & dosage. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / surgery. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning. XYY Karyotype


91. Numata A, Matsuishi E, Koyanagi K, Saito S, Miyamoto Y, Irie K, Gondo H, Harada M: Successful therapy with whole-lung lavage and autologous peripheral blood stem cell transplantation for pulmonary alveolar proteinosis complicating acute myelogenous leukemia. Am J Hematol; 2006 Feb;81(2):107-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful therapy with whole-lung lavage and autologous peripheral blood stem cell transplantation for pulmonary alveolar proteinosis complicating acute myelogenous leukemia.
  • A 43-year-old man with acute myelogenous leukemia (AML) was found to be complicated with pulmonary alveolar proteinosis (PAP), which was confirmed by biochemical and histological findings.
  • After achievement of complete remission of AML, he underwent whole-lung lavages twice between intensive chemotherapies.
  • Subsequently, he received high-dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT), which was performed safely without any infections.
  • [MeSH-major] Bronchoalveolar Lavage. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation. Pulmonary Alveolar Proteinosis / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16432866.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Betancourt-García RD, Castro J, Fernández AC, López-Enríquez A, Fradera J, Pacheco E: Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature. P R Health Sci J; 2009 Jun;28(2):146-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
  • Therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute myelogenous leukemia (t-AML) in patients with acute promyelocytic leukemia (APL) are rare events.
  • The cumulative exposure to chemotherapy with alkylating agents and topoisomerase II inhibitors is associated with t-AML that may develop any time after the completion of the treatment.
  • We report the case of an acquired AML who previously received therapy for APL, after two years of being diagnosed.
  • The diagnosis was established by morphologic findings, membrane markers, cytogenetic studies, and fluorescence in situ hybridization (FISH).
  • To our knowledge this is the first documented case in Puerto Rico of a patient with APL that developed a t-AML without the characteristic chromosomal and morphologic findings of APL.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasms, Second Primary / etiology. Translocation, Genetic


93. Chan G, Pilichowska M: Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood; 2007 Aug 1;110(3):1079-80
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Leukemia, Myeloid, Acute / therapy. Lung Neoplasms / therapy. Neoplasms, Second Primary / therapy. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage


94. Anensen N, Skavland J, Stapnes C, Ryningen A, Børresen-Dale AL, Gjertsen BT, Bruserud Ø: Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. Leukemia; 2006 Apr;20(4):734-6
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report.
  • [MeSH-major] Aminophylline / therapeutic use. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Li-Fraumeni Syndrome / complications. Li-Fraumeni Syndrome / therapy. Tretinoin / therapeutic use. Valproic Acid / therapeutic use

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. AMINOPHYLLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437140.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73; 27Y3KJK423 / Aminophylline; 5688UTC01R / Tretinoin; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


95. Sonmez M, Erkut N, Tat TS, Celep F, Cobanoglu U, Ersoz HO: Can a high platelet count be responsible for diabetes insipidus in acute myelogenous leukemia with monosomy 7 and inversion 3 (q21q26)? Int J Hematol; 2009 Sep;90(2):273-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can a high platelet count be responsible for diabetes insipidus in acute myelogenous leukemia with monosomy 7 and inversion 3 (q21q26)?
  • [MeSH-major] Chromosome Inversion. Diabetes Insipidus, Neurogenic / etiology. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / genetics. Thrombocytosis / complications


96. Yamazaki R, Mori T, Sugita K, Aisa Y, Ikeda Y, Okamoto S: Leuconostoc septicemia in a neutropenic patient with acute myelogenous leukemia relapsed after allogeneic peripheral blood stem cell transplantation. Transpl Infect Dis; 2009 Feb;11(1):94-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leuconostoc septicemia in a neutropenic patient with acute myelogenous leukemia relapsed after allogeneic peripheral blood stem cell transplantation.
  • [MeSH-major] Bacteremia / microbiology. Leuconostoc / isolation & purification. Leukemia, Myeloid, Acute / complications. Neutropenia / complications. Peripheral Blood Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19159417.001).
  • [ISSN] 1399-3062
  • [Journal-full-title] Transplant infectious disease : an official journal of the Transplantation Society
  • [ISO-abbreviation] Transpl Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  •  go-up   go-down


97. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A: Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia; 2008 Jul;22(7):1449-52
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.
  • [MeSH-major] Apoptosis / drug effects. Benzamides / pharmacology. Benzimidazoles / pharmacology. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Histone Deacetylase Inhibitors. Histones / metabolism. Leukemia, Myeloid, Acute / drug therapy. MAP Kinase Signaling System / drug effects. Promoter Regions, Genetic. Pyridines / pharmacology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18185526.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AZD 6244; 0 / Benzamides; 0 / Benzimidazoles; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Pyridines; 1ZNY4FKK9H / entinostat; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


98. Suresh P, Sharma A, Bhurani D: Treatment of myelodysplastic syndrome transforming into acute myelogenous leukemia with azacytidine: a retrospective study from cancer centre in northern India. Indian J Hematol Blood Transfus; 2010 Sep;26(3):114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of myelodysplastic syndrome transforming into acute myelogenous leukemia with azacytidine: a retrospective study from cancer centre in northern India.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21886398.001).
  • [ISSN] 0974-0449
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3002085
  •  go-up   go-down


99. Iwamoto M, Yamamoto H, Miyata T, Sunada K, Sugano K, Ozawa K: Leukemic cell infiltration into the large intestine in a patient with acute myelogenous leukemia. Gastrointest Endosc; 2008 Feb;67(2):353-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic cell infiltration into the large intestine in a patient with acute myelogenous leukemia.
  • [MeSH-major] Intestine, Large / pathology. Leukemia, Myeloid, Acute / pathology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226702.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Mantzios G, Tsirigotis P, Pappa V, Spirou K, Giannopoulou V, Kaitsa I, Girkas K, Papageorgiou E, Dervenoulas J: Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding. Eur J Haematol; 2007 Feb;78(2):173-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding.
  • [MeSH-major] Factor VII / adverse effects. Gastrointestinal Hemorrhage / drug therapy. Hemostatics / adverse effects. Leukemia, Myeloid / complications. Pulmonary Embolism / chemically induced. Thrombocythemia, Essential / complications. Thrombophilia / complications
  • [MeSH-minor] Acute Disease. Aged. Blood Transfusion. Combined Modality Therapy. Factor VIIa. Female. Femoral Vein. Fluid Therapy. Humans. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use. Salvage Therapy. Thrombolytic Therapy. Thrombophlebitis / chemically induced






Advertisement